Enveric Biosciences Announces Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update
Enveric Biosciences, a biotechnology company focused on developing next-generation neuroplastogenic small molecules for psychiatric and neurological disorders, has provided a comprehensive corporate update following the filing of its Form 10-K on March 27, 2026. The filing outlines the Company’s financial performance for the fourth quarter and full year ended December 31, 2025, along with progress across its research, development, intellectual property, and corporate initiatives.
The Company highlighted 2025 as a year marked by meaningful scientific advancement, particularly in strengthening the mechanistic and preclinical foundation of its lead drug candidate, EB-003. EB-003 is a non-hallucinogenic neuroplastogen being developed for the treatment of underserved mental health conditions, an area where current therapeutic options remain limited and often inadequate for patients with severe or treatment-resistant disorders.
According to Joseph Tucker, Ph.D., Chief Executive Officer of Enveric Biosciences, the Company’s research efforts throughout 2025 have continued to validate the dual mechanism of action associated with EB-003. This mechanism is designed to engage specific serotonin receptors, including 5-HT2A and 5-HT1B, in a manner that promotes neuroplasticity while avoiding hallucinogenic effects. Neuroplasticity, the brain’s ability to reorganize and form new neural connections, is widely recognized as a critical factor in the treatment of psychiatric conditions such as depression, anxiety, and post-traumatic stress disorder (PTSD).
Dr. Tucker noted that the Company has generated novel preclinical data supporting EB-003’s ability to enhance neuroplasticity in animal models without inducing hallucinogenic effects. These findings reinforce the Company’s strategy of developing therapies that combine efficacy with improved safety and scalability compared to traditional psychedelic compounds. Unlike hallucinogenic substances, which often require specialized administration settings and monitoring, non-hallucinogenic neuroplastogens could potentially be deployed more broadly in clinical settings.
The Company is currently advancing EB-003 through IND-enabling studies, which are necessary to support the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). Submission of the IND represents a key regulatory milestone that would allow Enveric to initiate first-in-human clinical trials. Dr. Tucker emphasized that the Company is working toward a streamlined IND submission pathway, following positive interactions with the FDA that have supported its development strategy.
In addition to internal research progress, Enveric highlighted recent independent academic findings that further support its scientific approach. External researchers have identified intracellular signaling pathways downstream of the 5-HT2A receptor that may mediate antidepressant and anxiolytic effects without triggering hallucinations. These findings align with Enveric’s hypothesis that it is possible to selectively activate therapeutic pathways while avoiding those responsible for hallucinogenic effects. The Company views this independent validation as reinforcing the broader neuroplastogen field and its own development strategy.
Another significant area of focus during 2025 was intellectual property. Enveric reported a successful defense of its patent portfolio, including the withdrawal of a Post-Grant Review (PGR) petition that had been filed by Gilgamesh Pharmaceuticals and later withdrawn by AbbVie Inc. This development was viewed by the Company as validation of the strength and breadth of its intellectual property assets, which are considered a critical component of its long-term value proposition.
The Company has continued to expand its intellectual property portfolio, securing multiple patents and notices of allowance across its compound series. Notably, Enveric strengthened its EVM301 Series with additional patent issuances and notices of allowance, while also unveiling the EVM401 Series of compounds in 2025. The EVM401 Series includes novel, non-hallucinogenic mescaline derivatives, with four issued U.S. patents, two of which were granted in the fourth quarter alone. These developments contribute to a growing portfolio of proprietary assets that support the Company’s pipeline and future commercialization opportunities.
In parallel with its scientific and IP advancements, Enveric has also pursued strategic business development initiatives. The Company executed licensing agreements with Restoration Biologics LLC, a biotechnology company focused on joint disease therapies, covering cannabinoid-COX-2 conjugate compounds for both pharmaceutical and potential non-pharmaceutical applications. Additionally, Enveric expanded its collaboration with TOTEC Pharma LLC through a trademark licensing agreement related to topical cannabinoid pharmaceutical products.
Operationally, the Company relocated its corporate headquarters to Cambridge, Massachusetts, a major global hub for biotechnology innovation. This move is intended to provide enhanced access to scientific talent, research collaborations, and financial resources, further supporting Enveric’s development activities and long-term growth strategy.
Financially, Enveric Biosciences reported a net loss attributable to stockholders of $4.0 million for the fourth quarter ended December 31, 2025. This included approximately $0.3 million in net non-cash expenses. The basic and diluted loss per share for the quarter was $6.12, compared to a net loss of $3.2 million in the same period of 2024, which included $1.0 million in net non-cash income and resulted in a loss per share of $58.06. The variation in loss per share reflects changes in share structure and non-cash accounting items between the two periods.
For the full year 2025, the Company raised gross proceeds of approximately $12.2 million through various financing activities, including offerings conducted during the year. In the fourth quarter alone, Enveric raised approximately $4.9 million through a combination of a warrant inducement transaction and an at-the-market (ATM) offering. These capital raises contributed to the Company’s cash position, which stood at $4.7 million as of December 31, 2025.
Subsequent to year-end, Enveric continued to access capital markets to support its operations and development programs. In January 2026, the Company raised approximately $1.5 million through a registered direct offering, followed by an additional $1.45 million raised in February 2026 via an ATM offering. These proceeds are expected to provide incremental funding for ongoing research, preclinical studies, and preparation for clinical trial initiation.
In terms of discovery research, Enveric reported progress in identifying additional neuroplastogenic candidates with the potential to modulate brain-derived neurotrophic factor (BDNF) signaling, a well-established pathway implicated in neurodegenerative and psychiatric disorders. BDNF plays a critical role in supporting neuron survival, growth, and synaptic plasticity, making it an important target for therapeutic intervention.
The Company also announced the publication of two peer-reviewed scientific articles describing novel bioproduction methods relevant to neuropsychiatric drug discovery. These studies, published in ACS Chemical Biology and BioDesign Research, outline new approaches for producing tryptamine- and MDMA-derived compounds. Such advances may contribute to more efficient and scalable methods for synthesizing complex molecules used in drug development.
Throughout 2025, Enveric maintained a strong emphasis on aligning its research, intellectual property, and business strategies. The Company’s integrated approach combines internal discovery efforts with external collaborations and partnerships to accelerate innovation in the neuropsychiatric space. By building a diversified pipeline of neuroplastogenic compounds and supporting technologies, Enveric aims to address a range of mental health conditions that currently lack effective treatment options.
Looking ahead to 2026, the Company’s primary focus remains the advancement of EB-003 toward IND submission and the initiation of a first-in-human Phase 1 clinical trial. Dr. Tucker expressed optimism that the dual-receptor mechanism of EB-003, which targets both 5-HT2A and 5-HT1B receptors, could enable meaningful therapeutic impact in conditions where innovation has historically been limited. The Company believes that its non-hallucinogenic approach may offer advantages in terms of safety, accessibility, and scalability compared to traditional psychedelic-based therapies.
Enveric also plans to continue expanding its intellectual property portfolio, advancing its discovery pipeline, and strengthening its collaborations within the biotechnology and pharmaceutical ecosystems. The Company’s presence in Cambridge is expected to support these efforts by facilitating access to academic institutions, research organizations, and industry partners.
In summary, Enveric Biosciences’ 2025 corporate update reflects steady progress across multiple dimensions of its business, including scientific development, intellectual property expansion, and financial management. With EB-003 advancing toward clinical evaluation and a growing portfolio of neuroplastogenic compounds, the Company is positioning itself within an emerging field focused on innovative approaches to treating psychiatric and neurological disorders. As it moves into 2026, Enveric remains focused on achieving key regulatory milestones and translating its research into potential therapeutic solutions for patients with significant unmet medical needs.
Source Link:https://www.businesswire.com/
